55+
Clinical Sites Worldwide
Including multiple FDA-approved trials in the U.S.
100%
Tumor Response
Observed in early-stage trials across all cancers treated
$50M+
Funding Secured
Sufficient runway to support operation through 2026 and beyond
New to Alpha Tau? Start here.
Alpha Tau has developed a breakthrough cancer therapy that destroys tumors from the inside — in a single treatment, with minimal side effects.
Called Alpha DaRT, it delivers highly localized alpha radiation directly into the tumor, while leaving surrounding healthy tissue almost untouched. In some cases, it may also help activate the immune system.
This is not chemotherapy. It’s not external radiation. And it’s already showing results.
In early-stage trials, 100% of patients responded to the treatment — with tumors shrinking or disappearing entirely. Side effects have been surprisingly mild.
The technology is now being used at 55+ clinical sites worldwide, including multiple FDA-approved trials in the U.S.
And it’s only the beginning.
Be part of the success
Alpha Tau is not just promising — it’s already delivering results.
The company has treated hundreds of patients across 55+ clinical sites worldwide.
In early-stage trials, 100% tumor response was observed across all cancers treated, including pancreas, lungs, breast, prostate, liver, brain and many more.
The company has been granted Breakthrough Device Designation by the FDA, was accepted into the FDA’s TAP program, and received an IDE approval for U.S. clinical trials.
Alpha DaRT is already approved for use in Israel for skin cancer and is expecting PMDA approval in Japan.
Alpha Tau is also collaborating with Merck, evaluating its therapy in combination with Keytruda — one of the world’s leading cancer drugs.
Preparing for commercialization, Alpha Tau has two manufacturing facilities already built — and a third under construction.
It has raised over $50 million in funding and is backed by leading global healthcare investors.
The total addressable market for this technology is estimated to exceed $100 billion.
Even a single indication like head & neck cancer could represent billions in annual revenue.
Latest Posts
